Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Protecting Effects of Gonadotropin-Releasing Hormone Agonist on Chemotherapy-Induced Ovarian Damage in Premenopausal Breast Cancer Patients: A Systematic Review and Meta-Analysis.

Bai F, Lu Y, Wu K, Chen Q, Ding L, Ge M, Weng Z.

Breast Care (Basel). 2017 Mar;12(1):48-52. doi: 10.1159/000454983. Epub 2017 Feb 28. Review.

PMID:
28611542
2.

Late effects of blood and marrow transplantation.

Inamoto Y, Lee SJ.

Haematologica. 2017 Apr;102(4):614-625. doi: 10.3324/haematol.2016.150250. Epub 2017 Feb 23. Review.

3.

Preserving Fertility in Children and Adolescents with Cancer.

Levine JM.

Children (Basel). 2014 Aug 26;1(2):166-85. doi: 10.3390/children1020166. Review.

4.

SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study.

Reimer T, Kempert S, Gerber B, Thiesen HJ, Hartmann S, Koczan D.

BMC Cancer. 2016 May 27;16:337. doi: 10.1186/s12885-016-2373-3.

5.

Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients.

Kim HJ, Yoon TI, Chae HD, Kim JE, Chae EY, Yu JH, Sohn G, Ko BS, Lee JW, Son BH, Ahn SH.

J Breast Cancer. 2015 Dec;18(4):365-70. doi: 10.4048/jbc.2015.18.4.365. Epub 2015 Dec 23.

6.

Cancer and fertility preservation: international recommendations from an expert meeting.

Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, Costa M, Revelli A, Salvagno F, Gennari A, Ubaldi FM, La Sala GB, De Stefano C, Wallace WH, Partridge AH, Anserini P.

BMC Med. 2016 Jan 4;14:1. doi: 10.1186/s12916-015-0545-7.

7.

Chemotherapy-Induced Amenorrhea - An Update.

Liedtke C, Kiesel L.

Geburtshilfe Frauenheilkd. 2012 Sep;72(9):809-818.

8.

Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis.

Shen YW, Zhang XM, Lv M, Chen L, Qin TJ, Wang F, Yang J, Liu PJ, Yang J.

Onco Targets Ther. 2015 Nov 13;8:3349-59. doi: 10.2147/OTT.S95936. eCollection 2015.

9.

Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.

Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, Marques RJ.

JAMA Oncol. 2016 Jan;2(1):65-73. doi: 10.1001/jamaoncol.2015.3251. Review.

10.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators.

N Engl J Med. 2015 Mar 5;372(10):923-32. doi: 10.1056/NEJMoa1413204.

11.

Fertility preservation and GnRHa for chemotherapy: debate.

Blumenfeld Z.

Cancer Manag Res. 2014 Aug 19;6:313-5. doi: 10.2147/CMAR.S66600. eCollection 2014. No abstract available.

12.

Fertility issues of breast cancer survivors.

McClellan Misiewicz H.

J Adv Pract Oncol. 2012 Sep;3(5):289-98. Review.

13.

Breast care.

[No authors listed]

Breast Care (Basel). 2012 Dec;7(6):501-4. doi: 10.1159/000345902. No abstract available.

14.

Utility of GnRH-agonists for Fertility Preservation in Women With Operable Breast Cancer: Is It Protective?

Bedoschi G, Turan V, Oktay K.

Curr Breast Cancer Rep. 2013 Dec 1;5(4):302-308.

15.

Fertility preservation options after gonadotoxic chemotherapy.

Hyman JH, Tulandi T.

Clin Med Insights Reprod Health. 2013 Apr 25;7:61-9. doi: 10.4137/CMRH.S10848. eCollection 2013 Apr 25. Review.

16.

Clinical guide to fertility preservation in hematopoietic cell transplant recipients.

Joshi S, Savani BN, Chow EJ, Gilleece MH, Halter J, Jacobsohn DA, Pidala J, Quinn GP, Cahn JY, Jakubowski AA, Kamani NR, Lazarus HM, Rizzo JD, Schouten HC, Socie G, Stratton P, Sorror ML, Warwick AB, Wingard JR, Loren AW, Majhail NS.

Bone Marrow Transplant. 2014 Apr;49(4):477-84. doi: 10.1038/bmt.2013.211. Epub 2014 Jan 13. Review.

17.

Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.

Zhang Y, Xiao Z, Wang Y, Luo S, Li X, Li S.

PLoS One. 2013 Nov 28;8(11):e80444. doi: 10.1371/journal.pone.0080444. eCollection 2013.

18.

Oncofertility in Canada: gonadal protection and fertility-sparing strategies.

Ronn R, Holzer HE.

Curr Oncol. 2013 Dec;20(6):e602-7. doi: 10.3747/co.20.1359.

19.

Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death.

Li F, Turan V, Lierman S, Cuvelier C, De Sutter P, Oktay K.

Hum Reprod. 2014 Jan;29(1):107-13. doi: 10.1093/humrep/det391. Epub 2013 Nov 12.

20.

Fertility counseling of young breast cancer patients.

Lambertini M, Anserini P, Levaggi A, Poggio F, Del Mastro L.

J Thorac Dis. 2013 Jun;5 Suppl 1:S68-80. doi: 10.3978/j.issn.2072-1439.2013.05.22.

Supplemental Content

Support Center